{"id":"NCT02898454","sponsor":"Sanofi","briefTitle":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","officialTitle":"A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-28","primaryCompletion":"2018-08-27","completion":"2018-11-16","firstPosted":"2016-09-13","resultsPosted":"2019-10-23","lastUpdate":"2019-10-23"},"enrollment":448,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893 (REGN668)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Mometasone furoate nasal spray","otherNames":["NASONEX®"]}],"arms":[{"label":"Dupilumab 300 mg q2w","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg q2w then q4w","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyps (NP). In addition for Japanese participants, reduction in computed tomography (CT) scan opacification of the sinuses was a co-primary objective.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of dupilumab in improving total symptoms score.\n* To evaluate the efficacy of dupilumab in improving sense of smell.\n* To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (primary objective for Japanese participants).\n* To evaluate ability of dupilumab in reducing proportion of participants who required treatment with systemic corticosteroids (SCS) or surgery for NP.\n* To evaluate the effect of dupilumab on participant reported outcomes and health related quality of life.\n* To evaluate the efficacy of dupilumab 300 mg q2w up to Week 52.\n* To evaluate the efficacy of dupilumab 300 mg q2w up to Week 24 followed by 300 mg every 4 weeks (q4w) up to Week 52.\n* To evaluate the effect of dupilumab in the subgroups of participants with prior surgery and comorbid asthma including non-steroid anti-inflammatory drug exacerbated respiratory disease.\n* To evaluate the safety of dupilumab in participants with bilateral NP.\n* To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatment emergent anti-drug antibodies.","primaryOutcome":{"measure":"Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.38,"sd":0.07},{"arm":"Dupilumab 300 mg (24 Weeks Pooled Arm)","deltaMin":-1.25,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":123,"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Israel","Japan","Mexico","Portugal","Russia","Spain","Sweden","Turkey (Türkiye)"]},"refs":{"pmids":["39343385","39151476","38854740","38156522","37453138","37322842","37026112","36721661","35775319","35636689","35092110","35034364","34970860","34954123","34911163","34850966","34817082","34459002","34437720","34037993","33993501","33710614","33611847","33548517","33465455","33226139","31543428"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":150},"commonTop":["Nasopharyngitis","Nasal Polyps","Headache","Asthma","Epistaxis"]}}